Sun Xianze, chairman of the Chinese Pharmaceutical Association, delivered a speech

In this meeting, the preparatory group of the Organizational Working Committee of the Chinese Pharmaceutical Association introduced the preparation and establishment process of the TCM Oncology Drug and Clinical Research Professional Committee to the participating members, and read out the list of the first chairman, vice chairman and members of the elected committee, and Mr. Zhang Min, chairman of Mengyang Pharmaceutical, was elected as a member of the first professional committee.

Professor Lin Hongsheng, chief researcher of the China Academy of Chinese Medical Sciences and deputy director of the Institute of Cancer of the China Academy of Chinese Medical Sciences, served as the chairman of the committee and delivered a speech to the conference, saying that under the leadership of the Chinese Pharmaceutical Association, he would work with authoritative experts in related industries to contribute to the research and development, evaluation and rational use of TCM cancer drugs. The implementation of the guidelines and all aspects of clinical practice provide practical help, improve the overall level of the industry, and promote the standardization and internationalization of TCM oncology drugs and clinical practice.

Professor Lin Hongsheng, Chairman of the Conference, delivered a speech

The establishment of the TCM Oncology Drugs and Clinical Research Committee is an information platform built by the Chinese Pharmaceutical Association to unite experts and scholars from scientific research institutions, clinical hospitals and pharmaceutical companies in the field of cancer research with the most influential international cancer research to jointly promote the scientific evaluation of TCM drugs for the treatment of tumors, and to promote the standardization and internationalization of the research and development of new TCM drugs and clinical research on tumors. The TCM Oncology Drugs and Clinical Research Committee will give full play to the advantages of industry organizations, organize academic exchanges at home and abroad, and promote the progress and development of new cancer TCM drugs in China.

Under the leadership of Chairman Zhang Min, Mengyang Pharmaceutical will keep up with the pace of the special committee, inherit the culture of traditional Chinese medicine, carry forward the advantages of traditional Chinese medicine, carry out the research and development of new traditional Chinese medicine, build a bridge for Sino-foreign "Belt and Road" cooperation, and lead traditional Chinese medicine to go abroad. The company's flagship product, Shengbai Oral Liquid, can be evaluated with quantitative indicators (white blood cell count), which also helps traditional Chinese medicine go abroad. Shengbai Oral Liquid is being registered with Health Canada, which will be a key step for the realization of traditional Chinese medicine products going abroad!

Zhang Min, chairman of Mengyang Pharmaceutical, was elected as a member of the first professional committee and took a group photo with Professor Lin Hongsheng, chairman of the conference

The professional committee took a group photo